The Biospecimen and Pathology Core ofthe Breast SPORE is responsible for accessioning and processing new biospecimens for the Breast SPORE Biospecimen Repository and to make those specimens available for use in the four SPORE main projects and very likely for the Developmental Research and Career Development Programs. Biospecimens will also be made available to other intra- and extra-mural investigators engaged in breast cancer translational research. Requests for biospecimens will be taken under consideration by the Breast SPORE Operations Committee, with a heavy emphasis on scientific merit and on availability of specimens and their associated data needed for analysis. Input from the Biostatistics and Patient Registry Core is included in the evaluation of requests for tissues. The Pathology Team of the Biospecimen Core will provide detailed annotations in the Breast Pathology Database for frozen and formalin-fixed paraffin-embedded tissues from selected cohorts of patients to support SPORE projects and additional projects for which the Breast Biospecimen Repository has provided tissues. The Core pathology team will also interpret IHC staining. The Biospecimen and Pathology Core will coordinate with the Mayo Clinic Cancer Center Biospecimen Accessioning and Processing Shared Resource to process blood samples to provide genomic DNA and serum aliquots, and with the Tissue and Cell Molecular Analysis Shared Resource to provide histology and other tissue-based services, including paraffin and frozen sectioning, immunohistochemistry, tissue microarray construction, and digital imaging. Working closely with existing infrastructure such as these shared resources minimizes redundancy of services and utilizes existing experience and state ofthe art equipment. New immunostaining assays will be developed by the Biospecimen and Pathology Core, as well as construction of cell line tissue microarrays to screen and test antibodies for immunostaining formalin-fixed, paraffin-embedded tissues.
The Biospecimen and Pathology Core provides the biospecimens (frozen tissue, FFPE tissue, tissue microarrays and cell line microarrays, blood, serum, DNA, and RNA), pathology annotations, histological services, and pathology support necessary to support the projects of the Mayo Clinic Breast Cancer SPORE as well as other breast cancer translational research projects. The Core also provides histology-related services, such as sectioning, immunostaining, antibody optimization and characterization, and digital imaging. Core pathologists provide IHC interpretations. These functions are essential to most translational research, including the specific projects included in this SPORE proposal.
|Abubakar, Mustapha; Orr, Nick; Daley, Frances et al. (2016) Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res 18:104|
|Cichon, Magdalena A; Moruzzi, Megan E; Shqau, Tiziana A et al. (2016) MYC Is a Crucial Mediator of TGFÎ²-Induced Invasion in Basal Breast Cancer. Cancer Res 76:3520-30|
|de la Hoya, Miguel; Soukarieh, Omar; LÃ³pez-Perolio, Irene et al. (2016) Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Hum Mol Genet 25:2256-2268|
|Durand, Nisha; Bastea, Ligia I; Long, Jason et al. (2016) Protein Kinase D1 regulates focal adhesion dynamics and cell adhesion through Phosphatidylinositol-4-phosphate 5-kinase type-l Î³. Sci Rep 6:35963|
|Shi, Jiajun; Zhang, Yanfeng; Zheng, Wei et al. (2016) Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. Int J Cancer 139:1303-17|
|Lei, Jieping; Rudolph, Anja; Moysich, Kirsten B et al. (2016) Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Hum Genet 135:137-54|
|(2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675|
|Li, Xu; Wang, Wenqi; Xi, Yuanxin et al. (2016) FOXR2 Interacts with MYC to Promote Its Transcriptional Activities and Tumorigenesis. Cell Rep 16:487-97|
|Schmidt, Marjanka K; Hogervorst, Frans; van Hien, Richard et al. (2016) Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J Clin Oncol 34:2750-60|
|Chiba, Akiko; Hoskin, Tanya L; Hallberg, Emily J et al. (2016) Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer. Ann Surg Oncol 23:3232-8|
Showing the most recent 10 out of 381 publications